RESUMO
Psychiatric and medical comorbidities are common among adults in the United States. Due to the complex interplay between medical and psychiatric illness, comorbidities result in substantial disparities in morbidity, mortality, and health care costs. There is, thus, both an ethical and fiscal imperative to develop care management programs to address the needs of individuals with comorbid conditions. Although there is substantial evidence supporting the use of care management for improving health outcomes for patients with chronic diseases, the majority of interventions described in the literature are condition-specific. Given the prevalence of comorbidities, the authors of this article reviewed the literature and drew on their clinical expertise to guide the development of future multimorbidity care management programs. Their review yielded one study of multimorbidity care management and two studies of multimorbidity collaborative care. The authors supplemented their findings by describing three key pillars of effective care management, as well as specific interventions to offer patients based on their psychiatric diagnoses and illness severity. The authors proposed short-, medium-, and long-term indicators to measure and track the impact of care management programs on disparities in care. Future studies are needed to identify which elements of existing multimorbidity collaborative care models are active ingredients, as well as which of the suggested supplemental interventions offer the greatest value.
Assuntos
Transtornos Mentais , Multimorbidade , Doença Crônica , Comorbidade , Custos de Cuidados de Saúde , Humanos , Transtornos Mentais/epidemiologia , Transtornos Mentais/terapia , Estados Unidos/epidemiologiaRESUMO
Objectives: To examine metabolic monitoring rates in commercially insured children and adolescents treated with a second-generation antipsychotic (SGA) during calendar years (CYs) 2016 and 2017. Methods: In this retrospective study, data were collected from a large national commercial health plan for the period covering January 1, 2016 to December 31, 2017. Commercially insured children and adolescents, aged 8-19 years with ≥2 SGA prescription claims during the CY, were identified for the CY2016 and CY2017 cohorts. The primary outcome of interest was the percentage of subjects with any glucose or lipid metabolism parameter monitoring. Other calculated metabolic testing rates included glucose, hemoglobin A1c (HbA1c), low-density lipoprotein cholesterol (LDL-C), other cholesterol (including triglycerides), and combined glucose and lipid metabolism testing (≥1 test for blood glucose or HbA1c and ≥1 test for LDL-C or other cholesterol). Results: In CY2016 and CY2017, 1502 and 1239 subjects, respectively, were identified for this study. The most common psychiatric diagnoses in CY2016 and CY2017 were major depressive disorder (57.1%, 56.5%, respectively), anxiety disorders (42.9%, 47.5%), attention-deficit/hyperactivity disorder (41.6%, 45.8%), and bipolar disorder (24.1%, 25.9%). The rate of any metabolic testing was 53.5% in CY2016 and 51.3% in CY2017. Glucose testing (50.3%, 46.9%, respectively) was most common in both CYs, followed by LDL-C testing (31.2%, 28.5%). Rates of combined glucose and lipid metabolism testing were 30.7% in CY2016 and 26.9% in CY2017. Conclusions: Given the known potential for adverse cardiometabolic effects, rates of metabolic monitoring associated with SGA use in children and adolescents urgently need to be improved. There is a critical need for understanding barriers to routine monitoring, particularly of lipids, and developing interventions to enhance metabolic monitoring.
Assuntos
Antipsicóticos/efeitos adversos , Glicemia/efeitos dos fármacos , Metabolismo dos Lipídeos/efeitos dos fármacos , Transtornos Mentais/tratamento farmacológico , Adolescente , Antipsicóticos/administração & dosagem , Antipsicóticos/farmacologia , Criança , Monitoramento de Medicamentos , Feminino , Humanos , Masculino , Estudos Retrospectivos , Estados Unidos , Adulto JovemRESUMO
The purpose of this paper is to provide clinicians a review of the literature on length of stay (LOS) in an effort to differentiate between superficial pressure from managed care and efficient inpatient care. We included papers that were identified through an OVID Medline search. Length of stay and psychiatry were entered as search variables. Limitations placed on the search were English language, as well as years 1990 to present. On review of the search results, all case reports and editorials were eliminated. Papers with abstracts indicating that LOS was not a primary focus of the paper were also eliminated. Lastly, one paper studying adolescent patients was eliminated to improve the homogeneity of the studies under consideration. The results and discussion are presented in a qualitative fashion, citing findings of individual studies. Effort was made to give weight to studies with large samples, good study design with explanation of any limitations or shortcomings of the individual studies, and powerful findings. What we found was that despite daily pressure upon clinicians to continually reduce LOS, the body of literature examining methods to achieve this goal without sacrificing quality, as well as the outcomes of reduced LOS, is quite sparse. As this measure affects clinical management and the doctor/patient relationship, further in depth studies are needed. It appears that the best way to fulfill the clinician's responsibilities to the patients and third party payers is through improving the services already provided to the patient.